Introduction and Context
Primary aldosteronism (PA) was once considered a rare cause of hypertension, thought to affect fewer than 1% of patients with high blood pressure. However, over the last decade, a paradigm shift has occurred. We now recognize that PA is the most common specifically treatable and potentially curable cause of hypertension, appearing in up to 20% of patients with resistant hypertension. More importantly, recent evidence, including the landmark findings from the Atherosclerosis Risk in Communities (ARIC) study, suggests that aldosteronism exists not as a binary ‘present or absent’ disease, but as a continuous spectrum of renin-independent aldosterone production.
This evolving consensus matters because excess aldosterone is toxic to the cardiovascular system, independent of its effect on blood pressure. It promotes fibrosis, inflammation, and oxidative stress in the heart and blood vessels. The latest research indicates that many individuals who do not meet the classic diagnostic criteria for PA still suffer from ‘subclinical’ aldosteronism, which places them at a heightened risk for devastating events like stroke and atrial fibrillation (AF).
New Guideline Highlights
The emerging expert consensus, supported by the 2026 ARIC cohort analysis, moves away from rigid biochemical cutoffs toward a risk-based assessment of the aldosterone-renin pathway. Key highlights include:
- The Spectrum Recognition: Clinicians should view aldosterone excess as a continuum. Even within ‘normal’ laboratory ranges, a higher Aldosterone-Renin Ratio (ARR) is associated with increased cardiovascular risk.
- Targeted Cardiovascular Prevention: There is a growing consensus that the aldosterone pathway is a primary target for preventing atrial fibrillation and ischemic stroke, particularly in older populations.
- Expansion of Screening: Recommendations are shifting toward screening a broader range of hypertensive patients, not just those with hypokalemia or resistant hypertension.
Updated Recommendations and Key Changes
Traditional guidelines, such as the 2016 Endocrine Society Clinical Practice Guideline, focused heavily on identifying patients for surgical cure (adrenalectomy). The new consensus expands this focus to medical management for the much larger ‘spectrum’ population.
| Feature | Previous Guideline Focus (e.g., 2016) | New Expert Consensus (2024-2026) |
|---|---|---|
| Prevalence | Rare (<1% of hypertensives) | Common (5-20% of hypertensives) |
| Diagnostic View | Binary (Disease vs. No Disease) | Spectrum (Continuous risk) |
| Primary Concern | Blood Pressure Control | Direct Organ Damage (AF, Stroke, Fibrosis) |
| Screening Trigger | Hypokalemia, Severe Hypertension | Most Hypertensives; Older adults with high ARR |
| Treatment Goal | Normalize Potassium & BP | Suppression of Renin-Independent Aldosterone |
The evidence driving these updates stems from large-scale longitudinal studies like ARIC, which followed 3,477 individuals over 9 years. The study found that a doubling of the ARR was associated with a 13% increased risk of stroke and a 10% increased risk of atrial fibrillation, even after adjusting for traditional risk factors.
Topic-by-Topic Recommendations
1. Diagnostic Criteria and the ARR
The Aldosterone-Renin Ratio (ARR) remains the most reliable screening tool. However, experts now suggest that an ARR in the ‘gray zone’ (e.g., 12–20 ng/dL per ng/mL/h) should not be dismissed as ‘normal,’ especially in the presence of left ventricular hypertrophy or unexplained AF. A suppressed renin level (5 ng/dL) suggests renin-independent production.
2. Risk Stratification
Patients should be stratified based on their ‘aldosterone burden.’ Older adults (aged 70+) are at particularly high risk. In the ARIC study, the median age was 75, and higher aldosterone activity was a potent predictor of stroke, regardless of whether the patient met the formal ‘Primary Aldosteronism’ definition.
3. Treatment Pathways
For patients on the spectrum who are not candidates for surgery, Mineralocorticoid Receptor Antagonists (MRAs)—such as spironolactone or eplerenone—are the treatment of choice. The consensus is shifting toward using MRAs earlier in the treatment algorithm for hypertension when renin is suppressed, rather than waiting for fourth-line therapy.
4. Special Populations
In patients with a history of atrial fibrillation or those at high risk for ischemic stroke, clinicians should have a low threshold for measuring ARR. Addressing the aldosterone-renin imbalance may be more effective for rhythm control than standard antihypertensive therapy alone.
Expert Commentary and Insights
Experts involved in the ARIC study and the latest consensus panels emphasize that the ‘old’ way of diagnosing PA misses the vast majority of patients at risk. “We have been looking for the tip of the iceberg—the overt, surgical cases—while ignoring the massive base of the iceberg: people with biochemical evidence of aldosterone excess that slowly destroys the heart and brain,” notes one commentator.
A major area of controversy remains the ‘confirmatory test.’ Many experts now argue that if a patient has a high ARR and suppressed renin, they should be treated with an MRA immediately, rather than undergoing expensive and often inconclusive salt-loading or fludrocortisone suppression tests, particularly if they are older or have heart disease.
Practical Implications: A Patient Vignette
Consider ‘Robert,’ a 74-year-old male with a history of moderate hypertension controlled by two medications. His blood pressure is 135/82 mmHg. Under old guidelines, Robert would never be screened for aldosteronism because his potassium is normal and his BP is ‘controlled.’ However, his doctor decides to check an ARR due to the new consensus. His aldosterone is 9 ng/dL and his renin is 0.2 ng/mL/h (ARR = 45).
Despite his ‘controlled’ BP, Robert is at a high risk for AF and stroke due to his renin-independent aldosteronism. Following the new recommendations, his physician adds a low-dose MRA to his regimen. This not only further stabilizes his BP but, more importantly, provides direct protection against the pro-arrhythmic and pro-fibrotic effects of aldosterone on his atrial tissue.
References
- Lassen MCH, Ostrominski JW, Claggett BL, et al. Spectrum of Primary Aldosteronism and Risk of Cardiovascular Outcomes: The Atherosclerosis Risk in Communities Study. JAMA Cardiology. 2026.
- Funder JW, Carey RM, Mantero F, et al. The Management of Primary Aldosteronism: Case Detection, Diagnosis, and Treatment: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2016;101(5):1889-1916.
- Brown JM, Robinson-Cohen C, Luque-Fernandez MA, et al. The Spectrum of Subclinical Primary Aldosteronism and Incident Hypertension: A Cohort Study. Ann Intern Med. 2017;167(9):630-641.
- Vaidya A, Mulatero P, Baudrand R, Rainey WE. The Expanding Spectrum of Primary Aldosteronism: Implications for Diagnosis, Pathogenesis, and Treatment. Endocrine Reviews. 2018;39(6):1057-1088.